Floatz logo

Cenvacibart

Venous Thromboembolism

Regeneron Pharmaceuticalsmonoclonal_antibodyPhase 3Active
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
95/ 100

Competitive context

14 Active assets in the Venous Thromboembolism cohort.

Asset / SponsorPhaseRating
WARFARIN
Northern Jiangsu People's Hospital
Phase 4A
Apixaban
Regeneron Pharmaceuticals
Phase 4BBB
Acetylsalicylic Acid
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 4BBB
NADROPARIN
Rijnstate Hospital
Phase 4BBB
Rivaroxaban
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 3BBB

View all 28 →

Same molecule, other indications

Cenvacibart is also rated in:

atrial fibrillationDormant
BB
Indicative ·
66 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →